March 25, 2024

A2 Bio Appoints James Robinson as New Chief Executive Officer and Member of the Board of Directors


March 4, 2024

A2 Bio Receives FDA Orphan Drug Designation for Novel Cell Therapy Program A2B530 in Colorectal Cancer


November 2, 2023

A2 Bio Presents Oral and Poster Presentations Highlighting BASECAMP-1 and EVEREST-1 Patient Screening at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting


October 16, 2023

A2 Bio Announces Oral and Poster Presentations at the 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting


May 30, 2023

A2 Bio Announces First Patient Dosed in Phase 1 Clinical Trial of A2B530, a Novel Cell Therapy for the Treatment of Colorectal, Pancreatic and Non-small Cell Lung Cancers


November 7, 2022

A2 Bio Identifying Solid Tumor Patients for Possible Inclusion in Phase 1 Studies Targeting CEA and Mesothelin Expected to Begin in 2023: Update at SITC 2022


March 4, 2022

A2 Bio’s Activator-blocker CAR-T Cell Therapies Show Early Promise in Solid Cancers


March 2, 2022

A2 Bio Publishes Key Preclinical Findings Demonstrating Potential of Its Highly Selective Tmod™ Cell Therapy Platform to Revolutionize the Treatment of Solid Tumors in Select Patients


January 18, 2022

A2 Bio to Present at ASCO-GI 2022 on Use of Next Generation Sequencing (NGS) to Identify GI Cancer Patients for Future TmodTM CAR T Therapy


November 12, 2021

A2 Bio Provides First Preclinical Data Presentation for CEA and MSLN Programs, Including Trial Update at SITC 2021


November 1, 2021

A2 Bio to Highlight Program Updates in Two Presentations at SITC 2021


January 13, 2021

Tempus Announces Companion Diagnostic Collaboration with A2 Biotherapeutics


December 23, 2020

A2 Biotherapeutics Enters into Collaboration Agreement with Merck to Develop Allogeneic Cell Therapy for Solid Tumor Cancers


October 6, 2020

A2 Biotherapeutics Closes $71.5M Series B to Begin Clinical Development of its Potentially Transformative Selective Tumor Cell Therapeutics


November 5, 2019

A2 Biotherapeutics Emerges From Stealth Mode With $57M Series A to Develop a Pipeline of Selective Tumor Cell Therapeutics